Brucella canis endophthalmitis in 3 dogs: clinical features, diagnosis, and treatment

• Published in: Veterinary ophthalmology 2009-05, Vol.12 (3), p.183-191
• Main Authors: Ledbetter, Eric C, Landry, Matthew P, Stokol, Tracy, Kern, Thomas J, Messick, Joanne B
• Format: Article
• Language: English
• Subjects: Animals; Anti-Bacterial Agents - therapeutic use; anti-inflammatory agents; Anti-Inflammatory Agents - therapeutic use; antimicrobial agents; Brucella canis; Brucella canis - isolation & purification; Brucella melitensis biovar Canis; brucellosis; Brucellosis - drug therapy; Brucellosis - microbiology; Brucellosis - veterinary; canine brucellosis; Canis; case studies; disease course; disease diagnosis; dog; dog diseases; Dog Diseases - diagnosis; Dog Diseases - drug therapy; Dog Diseases - microbiology; Dogs; endophthalmitis; Endophthalmitis - drug therapy; Endophthalmitis - microbiology; Endophthalmitis - veterinary; eye diseases; eyes; Female; inflammation; Male; uveitis
• ISSN: 1463-5216; 1463-5224
• DOI: 10.1111/j.1463-5224.2009.00690.x

To describe historical, clinical and diagnostic features of dogs with Brucella canis endophthalmitis and the response to medical therapy. Three dogs with naturally acquired B. canis endophthalmitis. Dogs were treated symptomatically with topical ophthalmic anti-inflammatories and a novel antimicrobial protocol that included doxycycline, enrofloxacin, rifampin and streptomycin. All dogs presented with chronic or recurrent uveitis in the absence of overt systemic disease. Clinical ophthalmologic abnormalities were unilateral in each dog and included mild-to-moderate anterior uveitis, iris hyperpigmentation, marked vitreal infiltrates, and multifocal chorioretinitis. Dogs were diagnosed with canine brucellosis serologically and by blood culture (n = 2 dogs) or polymerase chain reaction of aqueous humor and blood (n = 1 dog). Active ocular inflammation resolved in all dogs during treatment, with preservation of vision in 2 dogs. Following treatment, B. canis could not be cultured from blood samples and serological values declined with seronegativity achieved in all dogs after a median of 96 weeks (range: 36-112 weeks) of therapy. Brucella canis infection should be included in the differential diagnosis for dogs with intraocular inflammation, regardless of previous history or neuter status. This is the first report of apparently successful medical therapy of canine brucellosis with ocular involvement.